CAS: 41733-55-5; ——

该化合物是治疗与心脏衰竭,肝硬化和肾病以及高血压有关的水肿等条件时常用的强效循环二尿素,其作用是抑制甲酸钠-氯化钠共同运输器在肾脏环绕的厚厚的上方,导致钠,氯化物和水的排泄增加.这导致二尿素,有助于减少液体超负荷.氟化硫钠通常通过口服或静脉注射施用,并因其迅速开始作用而闻名.该化合物的特点是在水中溶性,便于其在临床环境中使用.副作用可能包括电解不平衡,脱水和潜在的食毒,特别是快速静脉注射.作为磺酰衍生物,它与其他二尿素的排泄物有结构相似性,但因其具体的行动和治疗机制而有所区别.

结构式图片

合成工艺路线路线简述

    海关参考信息

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Dotis J, Skarlatou A, Fourikou M, Papadopoulou A, Chochliourou E. Furosemide- Induced Nephrocalcinosis in Premature Neonates: A Critical Review of Observational Data. Children (Basel). 2025 Oct 24;12(11):1442. doi: 10.3390/children12111442.
    2: Singh MP, Maheshwari M, Singh J. Efficacy and Safety of Ionic Contra-Viral Therapy (Digoxin-Furosemide) in the Treatment of Multiple Cutaneous Warts: A Systematic Review, Meta-analysis, and Trial Sequential Analysis. Curr Drug Res Rev. 2025 Jul 24. doi: 10.2174/0125899775373642250630065739. Epub ahead of print. 78(3):127-131. 14(8):2595. doi: 10.3390/jcm14082595.
    5: Gudushauri N, Polintan ET, Lemonjava I, Menghrajani RH, Alfonso PG, Shah S, Azmaiparashvili Z, Lo KB, Rangaswami J. Torsemide vs. furosemide in congestive heart failure: a systematic-review and meta-analysis on mortality and rehospitalization. Acta Cardiol. 2025 Jun;80(4):351-357. doi: 10.1080/00015385.2025.2460406. Epub 2025 Feb 5. 2006–. Furosemide. 2025 Jan 15. 11(1):94-104. doi: 10.1093/ehjcvp/pvae083.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知